$434 Million is the total value of Sarissa Capital Management LP's 14 reported holdings in Q3 2016. The portfolio turnover from Q2 2016 to Q3 2016 was 20.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ARIA | ARIAD PHARMACEUTICALS INC | $175,916,000 | +85.3% | 12,850,000 | 0.0% | 40.51% | +50.3% | |
| BIIB | BIOGEN INC | $97,039,000 | +29.4% | 310,000 | 0.0% | 22.35% | +5.0% | |
| MDCO | MEDICINES CO | $66,120,000 | +12.2% | 1,752,000 | 0.0% | 15.23% | -9.0% | |
| ARRY | ARRAY BIOPHARMA INC | $29,025,000 | +89.6% | 4,300,000 | 0.0% | 6.68% | +53.8% | |
| PCRX | Sell | PACIRA PHARMACEUTICALS INC | $14,714,000 | -33.2% | 430,000 | -34.2% | 3.39% | -45.8% |
| INVA | New | INNOVIVA INC | $10,990,000 | – | 1,000,000 | +100.0% | 2.53% | – |
| ITCI | INTRA CELLULAR THERAPIES INC | $10,286,000 | -60.7% | 675,000 | 0.0% | 2.37% | -68.1% | |
| AEGR | AEGERION PHARMACEUTICALS INC | $7,867,000 | +99.3% | 2,649,000 | 0.0% | 1.81% | +61.8% | |
| ADXS | ADVAXIS INC | $6,413,000 | +32.1% | 600,000 | 0.0% | 1.48% | +7.3% | |
| APRI | APRICUS BIOSCIENCES INC | $4,898,000 | -15.3% | 14,479,052 | 0.0% | 1.13% | -31.3% | |
| DGX | Sell | QUEST DIAGNOSTICS INC | $4,231,000 | -67.3% | 50,000 | -68.6% | 0.97% | -73.5% |
| VVUS | VIVUS INC | $2,934,000 | +1.8% | 2,573,943 | 0.0% | 0.68% | -17.4% | |
| ABBV | Sell | ABBVIE INC. | $2,018,000 | -34.8% | 32,000 | -36.0% | 0.46% | -47.0% |
| AVEO | AVEO PHARMACEUTICALS INC | $1,780,000 | -7.4% | 2,000,000 | 0.0% | 0.41% | -24.9% | |
| PRGO | Exit | PERRIGO CO PLC | $0 | – | -100,000 | -100.0% | -2.57% | – |
| RPTP | Exit | RAPTOR PHARMACEUTICAL CORP | $0 | – | -2,875,000 | -100.0% | -4.38% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2016-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| BIOGEN INC. | 32 | Q3 2023 | 37.1% |
| INNOVIVA INC. | 29 | Q3 2023 | 19.5% |
| IRONWOOD PHARMACEUTICALS INC. | 24 | Q3 2023 | 24.2% |
| ABBVIE INC. | 23 | Q2 2020 | 24.4% |
| MEDICINES CO. | 20 | Q4 2019 | 33.9% |
| MERSANA THERAPEUTICS INC. | 19 | Q3 2023 | 7.9% |
| ALKERMES PLC | 16 | Q3 2023 | 43.7% |
| INTERCEPT PHARMACEUTICALS INC. | 15 | Q2 2021 | 10.7% |
| BIOCRYST PHARMACEUTICALS INC | 14 | Q3 2023 | 7.4% |
| VIVUS INC | 14 | Q1 2017 | 8.8% |
View Sarissa Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Alkermes plc. | August 24, 2023 | 8,323,400 | 5.0% |
| Innoviva, Inc. | May 15, 2023 | 6,904,000 | 10.5% |
| IRONWOOD PHARMACEUTICALS INC | March 01, 2021 | 14,890,000 | 9.3% |
| Iterum Therapeutics plcSold out | February 12, 2021 | 0 | 0.0% |
| BIOCRYST PHARMACEUTICALS INC | January 25, 2021 | 8,844,000 | 5.0% |
| Mersana Therapeutics, Inc. | January 25, 2021 | 3,770,000 | 5.5% |
| MEDICINES CO /DESold out | January 07, 2020 | 0 | 0.0% |
| Regulus Therapeutics Inc. | January 03, 2020 | 7,935,322 | 29.4% |
| NOVELION THERAPEUTICS INC. | November 09, 2018 | 909,296 | 4.6% |
| APRICUS BIOSCIENCES, INC. | September 05, 2018 | 1,152,455 | 4.8% |
View Sarissa Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-03-19 |
| 13F-HR | 2024-02-14 |
| 4 | 2023-12-19 |
| SC 13D/A | 2023-12-05 |
| 13F-HR | 2023-11-14 |
| 4 | 2023-09-19 |
| SC 13D/A | 2023-09-05 |
| SC 13D/A | 2023-08-24 |
| 13F-HR | 2023-08-14 |
| DFAN14A | 2023-06-28 |
View Sarissa Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.